Scientists test flu virus on volunteers to speed up vaccine development
NCT ID NCT06613737
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested different doses of an influenza A H3N2 virus in 33 healthy adults aged 18 to 55. The goal was to find a dose that safely causes mild flu symptoms, so this virus strain can be used in future trials to test new vaccines or treatments. Participants were monitored for side effects and infection rates over 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Influenza A H3N2 virus
- What this could lead to
- If successful, this study will help researchers safely test future flu vaccines and treatments by using a reliable virus strain that causes mild flu in volunteers.
- What could go wrong
- This is an early exploratory study with only 33 participants. The virus may not cause infection as expected, or side effects could be more than mild. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA A H3N2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
hVIVO Services Ltd, 40 Bank Street
London, E14 5NR, United Kingdom